Cyberonics Depression Approval Contingent On Dosing Trial, Registry
This article was originally published in The Gray Sheet
Executive Summary
Cyberonics will start a 450-patient, three-year dosing trial in order to gain PMA approval for its VNS Therapy neuromodulation device for use in treatment-resistant depression patients
You may also be interested in...
Schultz’ Controversial Approval Of Cyberonics Device Has Little Precedent
CDRH Director Dan Schultz's decision to override device and drug center review staff to approve Cyberonics' VNS Therapy neurostimulation device for treatment-resistant depression has scant precedent in recent history. All the same, he appears to have followed established FDA procedures
Schultz’ Controversial Approval Of Cyberonics Device Has Little Precedent
CDRH Director Dan Schultz's decision to override device and drug center review staff to approve Cyberonics' VNS Therapy neurostimulation device for treatment-resistant depression has scant precedent in recent history. All the same, he appears to have followed established FDA procedures
Senate Report Scrutinizes Schultz’ Role In Cyberonics’ Device Approval
A Senate Finance Committee report scrutinizes CDRH Director Daniel Schultz' role in FDA's controversial decision to approve Cyberonics' VNS Therapy neurostimulation device for treatment-resistant depression (TRD) in July 2005